Guangzhou Tinci Materials Technology (SHE:002709), through subsidiary Tinci Materials (Taizhou), will construct a high-pressure lithium iron phosphate plant for up to 2.10 billion yuan, according to a Shenzhen bourse filing on Wednesday.
The plant will annually produce 160,000 tons of lithium iron phosphate.
The Chinese new energy material manufacturer's shares rose 2% during the afternoon trade.
SANA Lifestyles, a wholly-owned subsidiary of Stanley Lifestyles (NSE:STANLEY, BOM:544202), has secured an order worth around 2 million Indian rupees from the Reserve Bank of India, according to a statement to the Indian stock exchanges on Wednesday.The contract is for the supply and installation of sofas and allied furniture products at RBI Chennai's main office.The order is expected to be completed in seven weeks.The company's shares were down nearly 1% in recent trade.
Jolimark (HKG:2028) said it was seeking HK$13.5 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.The printer manufacturer's shares gained over 33% in afternoon trade Wednesday.The company priced 122.6 million shares at HK$0.11 each to strengthen its financial position.The shares represent 20% of the company's issued share capital and 16.67% as enlarged by the issue.
TransThera Sciences (Nanjing) (HKG:2617) said Chinese regulators approved its phase 2 clinical trial of tinengotinib to treat prostate cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in afternoon trade Wednesday.The firm will evaluate a combination of tinengotinib and novel hormone therapy in an open-label study in subjects with metastatic castration-resistant prostate cancer.In a separate announcement, the firm said it is partnering with Shanghai Allist Pharmaceuticals on another open-label phase 2 study to evaluate TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer.Based on the results of the study, the parties may collaborate on a phase 3 study.